Table 1 Overview of patient demographics and clinical characteristics
From: Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas
| Number of patients (%) | |
|---|---|
| Gender | |
| Female | 27 (60%) |
| Male | 18 (40%) |
| Median age (years) at diagnosis (range) | 5.8 (0.4–18.3) |
| Histologic diagnosis | |
| Pilocytic Astrocytoma | 26(58%) |
| Pilomyxoid Astrocytoma | 2 (4%) |
| Diffuse Astrocytoma | 7 (16%) |
| Ganglioglioma | 5 (11%) |
| Desmoplastic Infantile Ganglioglioma (DIG) | 1 (2%) |
| Pleomorphic Xanthroastrocytoma (PXA) | 1 (2%) |
| Angiocentric glioma | 1 (2%) |
| Low grade glial or glioneuronal neoplasm, not otherwise specified (NOS) | 2 (4%) |
| Extent of first surgical resection (at diagnosis) | |
| Biopsy | 10 (23%) |
| Subtotal resection | 24 (50%) |
| Gross total resection | 11 (27%) |
| Median time (months) to first progressiona (Range) | 13 (1.5–178) |
| Median time (months) to second surgery (Range) | 19 (1.5–178) |
| Extent of second surgical resection | |
| Biopsy | 2 (4%) |
| Subtotal resection | 17 (38%) |
| Gross total resection | 22 (49%) |
| Unknown | 4 (9%) |
| Received systemic therapy prior to second surgery | 17 (38%) |
| Received at least two systemic therapy regimens prior to second surgery | 8 (17%) |
| Systemic therapy received (% of patients who received systemic therapy) | |
| Carboplatin with or without Vincristine | 12 (71%) |
| Vinblastine | 6 (35%) |
| Bevacizumab with or without Irinotecan | 3 (18%) |
| Temozolomide | 2 (12%) |
| Thioguanine, Procarbazine, Lomustine, and Vincristine | 2 (12%) |
| Carboplatin or Cisplatin, Cyclophosphamide, and Etoposide | 2 (12%) |
| Trametinib | 1 (6%) |
| Everolimus | 1 (6%) |
| Lenalinomide | 1 (6%) |
| Vorinostat | 1 (6%) |
| Rapamycin | 1 (6%) |
| Received irradiation prior to second surgery | 4 (9%) |
| Received no systemic therapy or irradiation prior to second surgery | 25 (56%) |
| Underwent third surgery | 4 (9%) |
| Median time (months) from second surgery to third surgery (range) | 38.5 (1–118) |
| Extent of third surgical resection | |
| Biopsy | 1 (25%) |
| Subtotal resection | 3 (75%) |
| Received systemic therapy between second and third surgeries | 2 (50%) |
| Systemic therapy received | |
| Temozolomide, then Vinblastine | 1 (20%) |
| Avastin and Irinotecan | 1 (20%) |
| Received irradiation between second and third surgery | 0 (0%) |
| Received no systemic therapy or irradiation between second and third surgeries | 2 (50%) |
| Underwent fourth surgical resection | 2 (4%) |
| Median time (months) from third surgery to fourth surgery (Range) | 45.5 (8–83) |
| Extent of fourth surgical resection | |
| Subtotal resection | 1 (50%) |
| Autopsy | 1 (50%) |
| Received systemic therapy between third and fourth surgeries | 2 (100%) |
| Systemic therapy received | |
| Temozolomide, then Trametinib | 1 (50%) |
| Lenalidomide, then Selumetinib, then Everolimus | 1 (50%) |
| Received irradiation between third and fourth surgery | 1 (50%) |
| Alive at time of last follow-up | 42 (93%) |
| Median time (months) to last follow-up (Range) | 87 (13–395) |